Sunday, November 02, 2014 2:15:11 PM
Hi STS
Re my funds
The FBIOX is an IRA account I've had for longer then I care to remember . As you know Fidelity has penalties if you trade their funds to often so this account is left alone unless it drops more then 15% in value.
IBB is the main position in my separate trading account that I may trade more frequently.
If either account drops 15% in value I move to 50% cash ..I'm very much into capital preservation
I am non diversified in that I am solely biotech ...but like they say "if you are going to have all your eggs in one basket ...watch that basket very closely ".
Most of my income is from my investments , so I spent a lot of time researching the macro trends driving biotech ( baby boomers driving demand etc ). I'm also fortunate to live in an area that has a high concentration of talented people doing research in the field and know a couple personally.
What I like about Biotech is that so much of the innovation in the field is happening here in the US , is somewhat immune to politics ( except pricing issues ..note GILD ) , wars , interest rates etc ...
Most small cap Bio's seemed doomed to failure but occaissonally you have these stars that burst onto the scene.
By the way ...anyone have an update on the CHERRY trial ..is data due this Qt or early 2015 ...if positive should be great for AMRN
Kiwi
Re my funds
The FBIOX is an IRA account I've had for longer then I care to remember . As you know Fidelity has penalties if you trade their funds to often so this account is left alone unless it drops more then 15% in value.
IBB is the main position in my separate trading account that I may trade more frequently.
If either account drops 15% in value I move to 50% cash ..I'm very much into capital preservation
I am non diversified in that I am solely biotech ...but like they say "if you are going to have all your eggs in one basket ...watch that basket very closely ".
Most of my income is from my investments , so I spent a lot of time researching the macro trends driving biotech ( baby boomers driving demand etc ). I'm also fortunate to live in an area that has a high concentration of talented people doing research in the field and know a couple personally.
What I like about Biotech is that so much of the innovation in the field is happening here in the US , is somewhat immune to politics ( except pricing issues ..note GILD ) , wars , interest rates etc ...
Most small cap Bio's seemed doomed to failure but occaissonally you have these stars that burst onto the scene.
By the way ...anyone have an update on the CHERRY trial ..is data due this Qt or early 2015 ...if positive should be great for AMRN
Kiwi
Recent AMRN News
- Amarin Highlights New REDUCE-IT Analysis Showing Risk-Weighted ApoB May Improve Cardiovascular Risk Detection (AMRN) • IH Market News • 05/27/2026 03:24:38 PM
- New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with Hypertriglyceridemia • GlobeNewswire Inc. • 05/27/2026 12:00:00 PM
- Earnings Report Shows Narrowing Losses as Amarin (AMRN) Advances Partner-Led Growth Strategy • IH Market News • 04/29/2026 02:19:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 11:06:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:05:15 AM
- Amarin Reports 2026 First Quarter Financial Results • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
